Apyx Medical Corp (APYX) COO exercises options for 12,000 shares

Rhea-AI Filing Summary

Apyx Medical Corp Chief Operating Officer Shawn David Roman reported an option exercise. On January 27, 2026, he exercised a stock option to purchase 12,000 shares of Apyx common stock at $1.80 per share under the company’s 2015 Share Incentive Plan.

The 12,000 shares acquired are held indirectly through The Roman Family Revocable Trust, where he serves as both trustee and beneficiary. Following the transaction, the reported stock option position was reduced to 0 derivative securities, with 12,000 common shares beneficially owned through the trust.

Insider Trade Summary

12,000 shares exercised/converted

Mixed 2 txns

Insider Roman Shawn David

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	12,000	$0.00	--
Exercise	Common Stock	12,000	$1.80	$22K

Holdings After Transaction: Stock option (right to buy) — 0 shares (Direct); Common Stock — 12,000 shares (Indirect, By The Roman Family Revocable Trust)

Footnotes (1)

1. Held by The Roman Family Revocable Trust of which Reporting Person is both a trustee and beneficiary. On January 27, 2026, the Reporting Person exercised his stock option awarded on March 16, 2016, to purchase 12,000 shares of the Issuer's common stock at a price of $1.80 per share pursuant to Issuer's 2015 Share Incentive Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roman Shawn David

(Last) (First) (Middle)

C/O APYX MEDICAL CORPORATION

5115 ULMERTON ROAD

(Street)

CLEARWATER FL 33760

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apyx Medical Corp [ APYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		M		12,000	A	$1.8	12,000	I	By The Roman Family Revocable Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.8	01/27/2026		M			12,000	(2)	03/15/2026	Common Stock	12,000	$0	0	D

Explanation of Responses:

1. Held by The Roman Family Revocable Trust of which Reporting Person is both a trustee and beneficiary.

2. On January 27, 2026, the Reporting Person exercised his stock option awarded on March 16, 2016, to purchase 12,000 shares of the Issuer's common stock at a price of $1.80 per share pursuant to Issuer's 2015 Share Incentive Plan.

	/s/ Shawn Roman	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apyx Medical Corp (APYX) report for its COO?

Apyx Medical’s Chief Operating Officer, Shawn David Roman, reported exercising a stock option to acquire 12,000 common shares. The transaction occurred on January 27, 2026, and reflects a move from derivative holdings into directly owned equity, indirectly held through a revocable family trust.

How many Apyx (APYX) shares were acquired and at what exercise price?

The filing shows the exercise of options for 12,000 shares of Apyx common stock at an exercise price of $1.80 per share. This converted a derivative position into 12,000 beneficially owned shares, all reported as indirectly held through The Roman Family Revocable Trust.

How is the 12,000-share Apyx Medical position held after the Form 4 transaction?

After the transaction, the 12,000 Apyx Medical common shares are reported as indirectly owned through The Roman Family Revocable Trust. Shawn David Roman is both a trustee and beneficiary of this trust, and the derivative stock option position reported in the filing was reduced to zero.

What happened to Shawn David Roman’s Apyx stock options in this Form 4?

The Form 4 shows a stock option, described as a right to buy, being exercised for 12,000 underlying shares. After exercising on January 27, 2026, the number of derivative securities beneficially owned in that option position became zero, reflecting full conversion into common stock.

When were the exercised Apyx Medical stock options originally granted?

The exercised stock option was originally awarded on March 16, 2016. According to the filing, Shawn David Roman used this option on January 27, 2026, to purchase 12,000 shares of Apyx Medical common stock at $1.80 per share under the 2015 Share Incentive Plan.

Under which equity plan were the Apyx (APYX) stock options granted and exercised?

The filing states that the option exercise was made pursuant to Apyx Medical’s 2015 Share Incentive Plan. On January 27, 2026, Shawn David Roman used this plan-based award, originally granted in March 2016, to acquire 12,000 shares of the company’s common stock at $1.80 per share.